Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

doi:10.1158/1078-0432.CCR-17-1523

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2018

Li Megan, Mulkey Flora, Jiang Chen, O'Neil Bert H, Schneider Bryan P, Shen Fei, Friedman Paula N, Momozawa Yukihide, Kubo Michiaki, Niedzwiecki Donna, Hochster Howard S, Lenz Heinz-Josef, Atkins James N, Rugo Hope S, Halabi Susan, Kelly William Kevin, McLeod Howard L, Innocenti Federico, Ratain Mark J, Venook Alan P, Owzar Kouros, Kroetz Deanna L

Abstract excerpt

Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Clinical Trials as Topic

Share to HSP90 Heat-Shock Proteins

Share to Human Umbilical Vein Endothelial Cells

Share to Hypertension

Share to Neovascularization, Pathologic

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 29871907
DOI: 10.1158/1078-0432.CCR-17-1523
PMCID: PMC6168379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).PMID 29871907Read ↗

Genetic markers of bevacizumab-induced hypertension.Semantic proximity Read ↗

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Semantic proximity Read ↗

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Semantic proximity Read ↗

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Semantic proximity Read ↗

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.Semantic proximity Read ↗

Genetic predisposition to bevacizumab-induced hypertension.Semantic proximity Read ↗

Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.Semantic proximity Read ↗

Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.Semantic proximity Read ↗

The role of vascular endothelial growth factor genetic variability in cancer.Semantic proximity Read ↗

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.Semantic proximity Read ↗

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.Semantic proximity Read ↗

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.